Check out the made in France dynamic phototherapy solution, a lighting system specially designed for the treatment of actinic keratoses.

Product picture

Our dermatological lighting has been specially designed to treat actinic keratosis using photodynamic therapy
Our Dermaris has been specially designed to treat actinic keratosis using photodynamic therapy
Our DERMARIS dermatological lighting on a mobile stand

DERMARIS

DERMARIS was specifically designed to treat actinic keratosis (AK) using photodynamic therapy (PDT). KA is a skin lesion that develops as a result of chronic & heavy exposure to the sun, which can evolve into skin cancer. Protoporphyrin IX (PpIX) is a molecule present in KA cells that multiplies under the effect of the precursor. Aminolevulinic acid methyl ester (AML) is the medication that acts as a precursor in the treatment of PDT.

PDT is a medical technique aimed at destroying pre-cancerous tissue through the use of photosensitising substances combined with a light source. This lighting provides a constant intensity of 20,000 lux and a wide and consistent treatment surface (20 cm). The irradiance spectrum of DERMARIS covers all the absorption peaks of the molecule that allows the destruction of pre-cancerous cells.

ASK FOR A QUOTE 👇

Key features

Benefits

DERMARIS has many benefits:
  • Ease of use: the lighting is compact and space-saving, making it easy to install patients (less than 2 minutes). Turning off the light head is easy as you just have to tilt it upwards to turn it off
  • Unrivalled patient comfort: the treatment is silent
  • Long-term use: over 30,000 treatments possible with a treatment time of 2h00
  • Durable lighting: DERMARIS has a service life of 60,000 hours and the possibility of using it as examination lighting. Furthermore, the lighting requires no consumables.

Clinical study

DERMARIS has been used in clinical study (1).

This is what the results show:

(study conducted on 38 people)

Efficiency:

  • 58% of patients were free of KA lesions 3 months after treatment
  • 32% of patients required a second AWL-PDT treatment
  • 10% of patients had one to four KA lesions after 2 treatments

Pain:

  • 33 of 38 patients (87%) felt no pain during the treatment
  • 5 patients (13%) rated their pain level as 1 on a 10-point scale

Post treatment:

The discomfort experienced during the six days following the treatment was described as follows:

  • Non-existent (34% of patients)
  • Mild (63% of patients)

 

(1) C Maire et al. Artificial white light photodynamic therapy for actinic keratosis: a study of 38 patients in private office practice (Letter to the editor). Journal of the European Academy of Dermatology and Venereology, Wiley, 2019. hal02503978.

Clinical experience & user studies

  • Photodiagnosis and Photodynamic Therapy

Clinical evaluation of a short illumination duration (1 hour) when performing photodynamic therapy of actinic keratosis using the Dermaris light source – M. Creusot, S. Mordon

  • Journal of the European Academy of Dermatology and Venerology

“Artificial white light photodynamic therapy for actinic keratosis : a study of 38 patients in private office practice” – C Maire, Anne-Sophie Vignion-Dewalle, H Cartier,
Serge Mordon

  • Journal of dermatological treatment

“A randomized split-face clinical trial of conventional vs indoor-daylight photodynamic therapy for the treatment of multiple actinic keratosis of the face and scalp and photoaging” Arisia, M. T. Rossia, L. Spiazzib, E. Guasco Pisania, A. Venturuzzoa, C. Rovatia, C. Tomasic, M. Venturinia and P. G. Calzavara-Pintona”

  • EURO PDT 2019

First clinical experiences on MAL-PDT with an artificial white light irradiation device (Dermaris®) in patients with multiple AK of the face and scalp: a split face study Schimtz L.

  • EURO PDT 2019

“Simulated daylight (SDL-PDT) treatment of AK with a new LED white light device : clinical results in a prospective observational pilot series in 30 patients Maire C, Mordon S.

  • EURO PDT 2019

Artificial white light PDT for AK : a study of 38 patients in private office practice Maire C, Vignion-Dewalle AS, Cartier H.

  • Dermatol Ther (Heidelb) (2022) 12:2049-2061

“Randomised clinical trial of conventional versus indoor daylight photodynamic therapy for the treatment of actinic cheilitis” – M. Arisi et al.

 

Review articles & scientific studies

  • Réalités Thérapeutiques en DERMATO-VENEROLOGIE

Thérapie photodynamique par lumière blanche artificielle pour le traitement des kératoses actiniques –S. Mordon, C. Maire

  • G Ital Dermatol Venereol. 2018 Dec;153(6):811-816

Can daylight-PDT be performed indoor ? Mordon S, Vignion-Dewalle AS, Thecua E, Vicentini C,
Maire C, Deleporte P, Baert G, Lecomte F, Mortier L. 

  • Journal of the European Academy of Dermatology and Venerology 

“Review of the European Society for Photodynamic Therapy (Euro-PDT) Annual Congress 2020” – Morton CA, Szeimies RM, Braathen LR

  • Photodiagnosis and Photodynamic Therapy

Clinical evaluation of a short illumination duration (1 hour) when performing photodynamic therapy of actinic keratosis using the Dermaris light source – M. Creusot, S. Mordon

Options

Additional protective glasses

Guarantee (& extended guarantee)

FAQ

DERMARIS is delivered with a pair of eye protection glasses for the patient
Our LEDs have a lifespan of 60,000 hours, more than 30,000 treatments!
DERMARIS is used in the treatment of actinic keratosis

Customer references

As a private dermatologist, I use photodynamic therapy to treat actinic keratoses.

Day light therapy is an effective treatment, but the use of DERMARIS by SURGIRIS allows an equivalent treatment to be carried out in the office with the same results. This treatment is done without the constraints of the weather. This technique can be performed comfortably in the office, both in summer and winter, without being dependent on rainy or hot weather.

I personally have 2 DERMARIS lamps for a better treatment of 2 “keratosis fields”, in a small dedicated room. Considering the frequency of this pathology, this equipment is quite profitable and useful for the patients.

Dr. Christiane BOULITROP
Dermatologue (Joigny, FRANCE)

WHY CHOOSE SURGIRIS PRODUCTS?

In our production facilities, we create high-performance operating theatre equipment for the most demanding applications.

More than 20 years of biomedical experience
Products 100% Made in France
International presence

    To top